Lifecore Biomedical

Q2 FY2026 EarningsQ2 FY2026 results delivered a top-line beat with revenue of $34.2M vs. $32.0M expected, driven by a 44% YoY surge in Hyaluronic Acid (HA) manufacturing. Despite the revenue beat, GAAP net loss of $6.2M was narrower than the $8.4M consensus, resulting in a diluted EPS loss of $0.19 which slightly outperformed the $0.22 mean expectation. Management reaffirmed FY2026 guidance, signaling confidence in a commercialization pivot for its late-stage CDMO pipeline.